Company Profiles
Portfolio 21 Holdings
- Abengoa
- Acciona
- Accor
- Adobe
- Agilent
- Air Liquide
- Air Products and Chemicals
- Applied Materials
- Atlas Copco
- Autodesk
- Aviva
- Baxter International
- Bristol-Myers Squibb
- British Land Company
- British Sky Broadcasting
- BT Group
- Canadian Pacific Railway
- Canon
- Carrefour
- Dell
- Denso
- Deutsche Bank
- Deutsche Post
- Dexia
- East Japan Railway
- Eaton
- Echelon
- EDF Energies Nouvelles
- Electrolux
- Ericsson
- Friends Provident
- Fuel Tech
- Gushan Environmental
- H. Lundbeck
- Henkel
- Hennes & Mauritz (H&M)
- Herman Miller
- Hewlett-Packard
- HSBC
- Husqvarna
- Hyflux
- Iberdrola Renovables
- IBM
- Intel
- Interface
- JM
- Johnson Controls
- Kao
- Kingfisher
- Kurita
- Linde
- Marks & Spencer
- Matsushita
- Mitsubishi Electric
- Mitsui O.S.K. Lines
- MTR
- Munich Re
- Nine Dragons
- National Express
- National Grid
- Natura Cosmeticos
- Netapp
- Nike
- Nokia
- Novartis
- Novo Nordisk
- Novozymes
- Olympus
- Ormat
- Philips Electronics
- Potlatch
- Praxair
- Prologis
- Red Electrica
- Reed Elsevier
- Royal Bank of Canada
- Schneider Electric
- Schnitzer Steel
- Severn Trent
- Sharp
- Shimano
- Siemens
- Skanska
- SKF
- Sompo Japan Insurance
- Sonoco
- Sony
- Staples
- STMicroelectronics
- Stora Enso
- Storebrand
- SunPower
- Suntech Power
- Svenska Cellulosa (SCA)
- Swedbank
- Swiss Re
- Swisscom
- Tandberg
- Teijin
- Telstra
- Telefonica
- TNT
- Tomra Systems
- Trex Company
- Trustpower
- UBS
- Umicore
- Unicredito Italiano
- United Natural Foods
- Verbund
- Vestas Wind Systems
- VMware
- Volvo Group
- Westpac Banking Corporation
- Whole Foods Market
- Xerox
Bristol-Myers Squibb
United States
Bristol-Myers Squibb aims to leverage responsible environmental management into a competitive advantage by manufacturing products that minimize negative economic and environmental impacts. An emerging issue for the pharmaceutical industry is the end-of-life impact of pharmaceuticals on aquatic life. Bristol-Myers Squibb recognizes this issue and is pursuing R&D in this area, as it continues to utilize green chemistry and product life-cycle analysis in its development process. The company provides sustainability training to a wide selection of its management and employees, and engages its suppliers to reduce their environmental impact. For example, work with just five of Bristol-Myers Squibb's suppliers in Puerto Rico resulted in savings of over $8 million in annual cost avoidance and $9 million in one-time savings. The environmental benefits of these improvements included reducing water use by more than 1.5 million gallons and reducing solid waste by almost 200,000 pounds. Innovative approaches to environmental issues have been prominent at Bristol-Myers Squibb. Examples include efforts to support biodiversity and mitigate the land-use impact of its facilities by committing to purchase and preserve biologically diverse land equivalent in size to its worldwide facilities. We commend the company's willingness to respond to stakeholder concerns related to the use of PVC in packaging; however, we have asked the company to report publicly on progress and to make a commitment to the elimination of PVC.
Biotechnology Involvement
Pharmaceutical company Bristol-Myers Squibb's medical application of biotechnology aims to provide healthy benefits while ensuring transparency. A committee with independent members from the local community addresses biotechnology concerns and stakeholder questions in public forums. The company has plans in place to prevent environmental releases of GM material. Visit our Biotechnology Policy for more on this issue.
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/30/07 and may not reflect current opinions or subsequent events.